Biora Therapeutics(BIOR)

Search documents
Biora Therapeutics Announces Funding Agreement with Existing Investors
GlobeNewswire News Room· 2024-08-12 20:05
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced the signing of financing agreements with its existing convertible notes holders. "We appreciate the continued commitment of our existing noteholders, who have agreed to an additional investment in Biora that we expect will fund us to important milestones, including anticipated partnering with large pharma," said Eric d'Esparbes, Chief Financial Officer o ...
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
GlobeNewswire News Room· 2024-08-08 20:30
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the second quarter ended June 30, 2024. Company management will host a webcast and conference call on Monday, August 12, 2024, after the close of financial markets. Conference Call and Webcast Information Date: Monday, August 12, 2024 Time: 4:30 PM Eastern time / 1:30 PM Pacific time Con ...
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Newsfilter· 2024-07-18 12:00
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, presented supplemental data from the Phase 1 trial of BT-600 during the company's virtual KOL event on Wednesd ...
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Newsfilter· 2024-07-08 12:00
A replay will be available online following the event. About Bruce Sands, MD, MS Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Sands was awarded his BA and MD from Boston University, and trained in internal medicine at the Hospital of the University of Pennsylvania. After completing GI fellowship at the Massachusetts General Hospital, he joined the faculty of Harvard Medical School and served as the Acting Chief of the ...
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
Newsfilter· 2024-06-11 12:00
For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter. Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. Media Contact media@bioratherapeutics.com Details of the presentation are as follows: Presentation Title: Empowering Peptide Self Administration with Needle-Free Smart Capsules Track: Pioneering Devices to Increase the Reach o ...
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
globenewswire.com· 2024-05-20 12:00
SAN DIEGO, May 20, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented a poster titled "Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC" at the Digestive Disease Week® conference in Washington DC, on Sunday, May 19, 2024. "In four separate clinical studies, we evaluated the functionality and safety of the NaviCap device in healthy particip ...
Biora Therapeutics(BIOR) - 2024 Q1 - Earnings Call Transcript
2024-05-15 22:29
Financial Data and Key Metrics Changes - The net loss for the first quarter of 2024 was $4.2 million, which included noncash stock-based compensation expenses and gains from changes in warrant liabilities [26] - Operating expenses, excluding stock-based compensation, were $40.5 million, with a core operating cash burn of $11.5 million for the quarter [50][26] - The company reduced its convertible note balance to approximately $52 million by the end of the first quarter, reflecting strong institutional investor confidence [14] Business Line Data and Key Metrics Changes - The NaviCap platform's clinical trial for BT-600 in ulcerative colitis (UC) showed that all devices performed as intended and were well tolerated, with complete colonic coverage achieved [78][96] - The BioJet platform demonstrated an average bioavailability of over 20% for animals with detectable drug in blood, indicating progress in oral delivery of large molecules [82] Market Data and Key Metrics Changes - The company is actively engaging with potential partners for the BioJet platform, with strong interest from both current collaborators and new companies [4][36] - The anticipated clinical study with BT-600 in UC patients is expected to begin in the second half of 2024, indicating a strategic focus on expanding clinical applications [5] Company Strategy and Development Direction - The company aims to optimize tofacitinib therapy in UC by achieving higher drug exposure in colon tissue without high systemic exposure, addressing a significant unmet need in UC patients [80][96] - The focus for the BioJet platform is on progressing towards partnerships in 2024, with an emphasis on bringing the technology to clinical applications [88] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming data from the BT-600 clinical trial, which is expected to provide insights into the efficacy of the NaviCap platform [88][52] - The company is focused on maximizing value and maintaining optionality in negotiations with potential partners, aiming for serious partnerships that lead to clinical trials [69] Other Important Information - The company has made significant progress in reducing its net debt, achieving a 75% reduction in 2023 alone, and continues to optimize its capital structure [86] - The NaviCap platform is designed to provide targeted delivery of therapeutics directly to the site of disease in the colon, which is crucial for treating UC effectively [96] Q&A Session Summary Question: What are the expectations for the BT-600 top line data? - Management indicated that confirmation of single ascending dose (SAD) data would be considered a success, as it supports colonic uptake and delivery [20] Question: What factors might influence the go/no-go decision for the adalimumab biosimilar program? - Management noted that they are encouraged by early data and are looking to take the BT-600 program further, which could inform the adalimumab program [64] Question: How is the company framing expectations for the UC study design? - Management stated that they are finalizing protocols and will make determinations based on the MAD data and expert consultations [52]
Biora Therapeutics(BIOR) - 2024 Q1 - Quarterly Report
2024-05-15 20:30
Common Stock, par value $0.001 per share BIOR The Nasdaq Global Market ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 For the transition period from to Delaware 27-3950390 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Registrant's telephone number, including area code: (833) 727-2841 Indicate by check mark whether the registrant (1) has filed all reports required to ...
Biora Therapeutics(BIOR) - 2024 Q1 - Quarterly Results
2024-05-15 20:10
Biora Therapeutics Provides Corporate Update and Reports Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Partnering process for the BioJet oral delivery platform is progressing well SAN DIEGO, May 15, 2024 – Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. "We continue to ...
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
Newsfilter· 2024-05-06 12:00
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data on device function of the NaviCap™ Targeted Oral Delivery Platform at Digestive Disease Week® (DDW), which will take place both virtually and in-person May 18-21, 2024 in Washington, DC. Details of the presentations are as follows: Abstract Title:Results of Human Device Function Studies for the NaviCap™ Targeted O ...